Edition:
United Kingdom

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

164.95USD
23 May 2018
Change (% chg)

$-2.14 (-1.28%)
Prev Close
$167.09
Open
$165.98
Day's High
$167.39
Day's Low
$164.93
Volume
163,912
Avg. Vol
137,616
52-wk High
$168.64
52-wk Low
$128.58

Select another date:

Wed, May 9 2018

Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

UPDATE 2-Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON, May 8 Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON, May 8 Jazz Pharmaceuticals plc on Tuesday said that it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

BRIEF-Jazz Pharmaceuticals Reports Q1 Adjusted Earnings Per Share $2.98

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Jazz Pharma Submits Supplemental New Drug Application For Xyrem To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

* JAZZ PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR XYREM® (SODIUM OXYBATE) TO TREAT CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd

* SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING

BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

* JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA

BRIEF-Jazz Pharmaceuticals Q4 GAAP Earnings Per Share $3.79

* JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-Jazz Pharmaceuticals Enrolls First Patient In Clinical Trial of Defibrotide

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL EVALUATING DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE Source text for Eikon: Further company coverage:

BRIEF-Jazz Pharma Submits New Drug Application For Solriamfetol (JZP-110)

* JAZZ PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY AND OBSTRUCTIVE SLEEP APNEA

Select another date: